| Symbol | BIIB |
|---|---|
| Name | BIOGEN INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 225 BINNEY STREET, CAMBRIDGE, Massachusetts, 02142, United States |
| Telephone | +1 617 679-2000 |
| Fax | — |
| — | |
| Website | https://www.biogen.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Biogen and Idec merged in 2003, combining forces to market Biogens multiple sclerosis drug Avonex and Idecs cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogens MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firms first Alzheimers disease therapy in June 2021. Additional info from NASDAQ: |
New Form ARS - BIOGEN INC. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001193125-26-187407 <b>Size:</b> 1 MB
Read moreNew Form DEFA14A - BIOGEN INC. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001193125-26-187383 <b>Size:</b> 856 KB
Read moreNew Form DEF 14A - BIOGEN INC. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001193125-26-187303 <b>Size:</b> 8 MB
Read moreBiogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
Read moreTJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
Read moreNew Form 3 - BIOGEN INC. <b>Filed:</b> 2026-04-06 <b>AccNo:</b> 0000950157-26-000479 <b>Size:</b> 9 KB
Read moreGodbout Sean 🟡 adjusted position in 54 shares (1 derivative) of BIOGEN INC. (BIIB) at $183.78 Transaction Date: Apr 01, 2026 | Filing ID: 000036
Read moreBiogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Read moreFDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Read more